Evidence map›Paper›PMID 40807229›Full record

ArticleMolecules (Basel, Switzerland)2025

Modulatory Effect of Curcumin on Expression of Methyltransferase/Demethylase in Colon Cancer Cells: Impact on wt p53, mutp53 and c-Myc.

Roberta Santarelli, Claudia Di Dio, Michele Di Crosta, Paola Currà, Roberta Gonnella, Mara Cirone

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Development of a prognostic prediction model incorporatingJournal of gastrointestinal oncology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Roberta SantarelliDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-9416-7594
Claudia Di DioDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Michele Di CrostaDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Paola CurràDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Roberta GonnellaDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-4894-4986
Mara CironeDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-2207-9624

Funding

Italian Association for Cancer Research IG2019-23040
6 · The paper itself

Abstract

Curcumin-mediated anti-cancer properties have been correlated with the inhibition of oncogenic molecules such as mutp53 and c-Myc. Their targeting is therapeutically significant, as p53, following point mutations, can acquire oncogenic functions, and c-Myc overexpression, due to translocations, point mutations, protein/protein interactions, or epigenetic modifications, plays a central role in cancer cell proliferation and metabolic reprogramming, particularly in colorectal cancer. In a previous study, we showed that curcumin strongly downregulated mutp53 while activating wtp53 and reduced the expression of methyltransferases such as EZH2, G9a, and MLL-1 in colon cancer cells. Based on this background, here we investigated whether the dysregulation of such methyltransferases could correlate with the effect observed on p53. We also explored whether these epigenetic changes could affect c-Myc expression in these cells. By Western blot analysis and RT-qPCR, we found that the downregulation of EZH2; G9a; and, to a lesser extent, KDM1, which was also reduced by curcumin, correlated with the decrease in mutp53 and that the reduction of EZH2 and KDM1 correlated with the activation of wtp53. Regarding c-Myc, we unveiled the occurrence of a positive feedback loop between it and MLL-1, which was inhibited by curcumin, independently of the p53 status. In conclusion, this study provides new insights into the therapeutic potential of curcumin, which involves its properties to act as an epigenetic modulator and target key molecules in colon cancer cells.

Indexed as

Colonic NeoplasmsCurcuminHistone DemethylasesMethyltransferasesProto-Oncogene Proteins c-mycTumor Suppressor Protein p53Cell Line, TumorCell ProliferationEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticGene Expression Regulation, NeoplasticHistone-Lysine N-MethyltransferaseHumansCurcuminEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistone DemethylasesHistone-Lysine N-MethyltransferaseMethyltransferasesMYC protein, humanProto-Oncogene Proteins c-mycTP53 protein, humanTumor Suppressor Protein p53c-Myccolon cancerdemethylaseslysine methyltransferasep53

Identifiers

PMID40807229
PMCPMC12348775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.